Abstract
Background Genomic risk prediction models for breast cancer (BC) have been predominantly developed with data from women aged less than 70 years. Prospective studies of women aged 70 years or older have been limited.
Methods We assessed the effect of a 313-variant polygenic risk score (PRS) for BC in 6,339 women of European ancestry aged ≥70 years. We evaluated incident BC diagnoses over a median follow-up of 4.7 years. A multivariable Cox regression model including conventional risk factors was applied to prospective data, and re-evaluated after adding the PRS. We also assessed the association of rare pathogenic variants (PVs) with BC in susceptibility genes (BRCA1/BRCA2/PALB2/CHEK2/ATM).
Results The PRS, as a continuous variable, was an independent predictor of incident BC (hazard ratio [HR] per standard deviation (SD)=1.4, 95% confidence interval [CI] 1.3-1.6, N=110 cases) and hormone receptor (ER/PR)-positive disease (HR=1.5 [CI 1.2-1.9], N=79 cases). Women in the top quintile of the PRS distribution had higher risk of BC than women in the lowest quintile (HR=2.2 [CI 1.2-3.9]). The concordance index of the model without the PRS was 0.62 (95% CI 0.56-0.68) which improved after addition of the PRS to 0.65 (95% CI 0.59-0.71). Among 41 (0.6%) carriers of PVs in BC susceptibility genes, we observed no incident BC diagnoses.
Conclusion The 313-variant PRS predicts BC risk in women aged 70 years and older.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01038583
Funding Statement
This work was supported by an ASPREE Flagship cluster grant (including the Commonwealth Scientific and Industrial Research Organisation, Monash University, Menzies Research Institute, Australian National University, University of Melbourne); and grants (U01AG029824 and U19AG062682) from the National Institute on Aging and the National Cancer Institute at the National Institutes of Health, by grants (334047 and 1127060) from the National Health and Medical Research Council of Australia, and by Monash University and the Victorian Cancer Agency. AEC receives a NHMRC Career Development Fellowship (1147843). HPS holds an NHMRC MRFF Next Generation Clinical Researchers Program Practitioner Fellowship (APP1137127). PL is supported by a National Heart Foundation Future Leader Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received local ethics committee approval from the Alfred Hospital Research Ethics Committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data underlying this article will be shared on reasonable request to the corresponding author.
